Select your language
Select your language
Press release of the Leibniz Center Infection from January, 20, 2023-- translated from German
International Symposium of the Leibniz Center Infection
Hamburg. The multiple strategies of infectious pathogens to survive and multiply in the host and how we might use these sophisticated strategies to better fight the pathogens are the focus of this year's symposium "Compartments in Infection" of the Leibniz Center Infection (LCI). On January 26 and 27, 2023, international researchers will gather at the Bernhard Nocht Institute for Tropical Medicine to discuss this topic.
Antimicrobial resistance (AMR) claimed 5 million lives in 2019, posing a major challenge to global public health. National action plans (NAPs) are the primary method for guiding national strategies and actions to combat AMR. Although several NAPs have been developed, there is no comprehensive content analysis of these plans. A team of different researchers, including 3 members of our alliance, conducted a systematic assessment of NAP implementation in 114 countries.
The multidrug-resistant opportunist Stenotrophomonas maltophilia plays a central role in one of our projects: it is part of mixed biofilms in which the interactions between pulmonary opportunists and emerging antimicrobial resistance are studied (IPT2, further description HERE). At the highly respected American Society for Microbiology (ASM) conference "ASM Microbe 2022" held in June, there was intense discussion about this pathogen, which is increasingly developing resistance to conventional drugs. The video recorded live in Washington DC is available HERE .
Press Release of the Autonomous University of Barcelona (UAB), 05.09.2022
Researchers from the Bacterial Pathogenesis and Antimicrobials group of the Institut de Biotecnologia i de Biomedicina (IBB) and the Department of Genetics and Microbiology at UAB, have evaluated several compounds that have been shown to inhibit biofilm formation in important opportunistic human pathogens. The targets of these molecules include multidrug-resistant Gram-negative and Gram-positive pathogenic bacteria as well as the fungal pathogen Candida albicans. The study was carried out in a collaboration which involved three more European laboratories.
Since May, 31 we can be pleased about a new associated project in our alliance:
Vitality
More than 2 million children globally live with HIV, 90% of them in sub-Saharan Africa. Vitality is an EDCTP (European & Developing Countries Clinical Trials Partnership) funded clinical study in Zambia and Zimbabwe analysing the effect of vitamin D supplementation on health improvement of HIV-positive children.